Evolus vs Rigel Pharmaceuticals
Evolus and Rigel Pharmaceuticals are similar in size: $297m and $294m of revenue in their latest fiscal years. Rigel Pharmaceuticals grew faster (64.1% against 11.6%). Rigel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 124.7% against -17.4%.
| Latest fiscal year | EvolusEOLS, 2025 | Rigel PharmaceuticalsRIGL, 2025 |
|---|---|---|
| Revenue | $297m | $294m |
| Revenue growth | 11.6% | 64.1% |
| Net income | −$51.6m | $367m |
| Operating margin | -11.0% | 42.6% |
| Net margin | -17.4% | 124.7% |
| Return on equity | — | 185.9% |
| Free cash flow | −$45.7m | $75.7m |
| Cash | $53.8m | $40.6m |
| Total debt | $150m | $52.5m |
| Debt to equity | — | 13.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 334 | — |
| Market value | $481m | $889m |
| Price vs our value range | — | Below our value range |
| Moat score | 10 (Weak) | 29 (Weak) |
| Insider trades, 12 months | 0 buys, 7 sales | 0 buys, 3 sales |